NewImage

The COVID-19 pandemic has had a substantial impact on global health and highlighted the importance of international cooperation to effectively combat SARS-CoV-2. Since the discovery and publication of the virus’s genome in January 2020, scientists have rushed to develop vaccines, therapeutics and diagnostics on an unprecedented timescale. To date there are 80 vaccines in clinical trials and 70 more in clinical development, setting the stage for some of the fastest vaccine development and testing in modern history1. The vaccine technology platforms used by the most promising vaccine candidates range from viral vector–based and protein-based technologies to mRNA and lipid nanoparticle technology. Despite these impressive scientific achievements, barriers such as the vaccine cold chain and multiple forms of intellectual property (IP) protection stand in the way of equitable access and fair allocation.

Image: https://www.nature.com

ssti logo

The April jobs report, released by the Bureau of Labor Statistics on May 7, generated considerable attention due to the 266,000 jobs added being far less than anticipated. Contributing to this topline number are quite a few trends moving in different directions, including a severe decline in automotive manufacturing employment — likely driven by the global semiconductor shortage — increasing restaurant and R&D employment, and declines in part-time work. Ultimately, the April employment data suggest a far more complex portrait of the economy than what is being covered in many sources.

 

app

The universal impact of the COVID-19 pandemic has forever changed our understanding of the lives we knew both collectively and personally. No one is immune to the effects of an “enemy” that we cannot see and at times cannot comprehend.

It would be safe to say that feelings of uncertainty and uneasiness are a normal part of our daily lives over the past year. Regaining a sense of control and the promise of returning to some semblance of safety and normalcy is a priority.

 

Lankenau Logo

WYNNEWOOD, PA / ACCESSWIRE / May 19, 2021 / Lankenau Ventures is a new business established to accelerate development and commercialization of medical inventions conceived by frontline healthcare workers. It is an initiative comprising a leading medical research institute and commercialization and entrepreneurship experts.

The joint venture includes the Lankenau Institute for Medical Research (LIMR; the research division of Main Line Health) and L2C Partners, both in Philadelphia and Early Charm in Baltimore.

NewImage

The Terp Entrepreneur Network (TEN) is a University of Maryland Alumni Association industry-focused group with a broad mandate to foster a vibrant Terp alumni entrepreneurship ecosystem. Bringing together UMD’s significant investments in innovation and our talented network of alumni, TEN generates tremendous value for the Terp community. TEN serves as a dedicated platform to connect Terp alumni with the resources, tools, and connections needed in meaningful ways to advance their entrepreneurial goals.

 

NewImage

FastForward U has announced the winners of its inaugural Innovation & Entrepreneurship Challenge, which awarded more than $100,000 to eight student startups.

The I&E Challenge gave students a streamlined process to apply for multiple funding opportunities that enable them to make progress on their ventures over the summer without having to balance a job or internship. All four awards include money to pay for room and board, co-working space at FastForward U, and access to mentors and advisers.

Image: https://hub.jhu.edu

Amritha Jaishankar, Ph.D.

The Maryland Stem Cell Research Commission announces the appointment of Amritha Jaishankar, Ph.D. as Executive Director, Maryland Stem Cell Research Fund (MSCRF). In her role as the Executive Director of the Maryland Stem Cell Research Fund, Amritha oversees all MSCRF activities and six programs accelerating stem cell research, commercialization, and cures. She will remain committed to helping our scientists, physicians, and companies advance their research and deliver cures to patients in need.

 

Cursor and Had You Purchased Alexandria Real Estate Equities in 2001 Here s Your Result My Morning Joe Stock Watch

The investment philosophy practiced by Warren Buffett calls for investors to take a long-term horizon when making an investment, such as a twenty year holding period (or even longer), and reconsider making the investment in the first place if unable to envision holding the stock for at least five years. Today, we look at how such a long-term strategy would have done for investors in Alexandria Real Estate Equities Inc (NYSE: ARE) back in 2001, holding through to today.

Image: https://mmjstockwatch.com

BHI Logo

Are you a biohealth start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Schedule your feedback session with BHI EIRs on one of the following dates. Pre-registration is required; Sign up here tinyurl.com/EIRfeedback

For questions/more information, contact BHI.

 

BHI NIH Logo

BioHealth Innovation, Inc. (BHI), is a Montgomery County innovation intermediary which translates market-relevant research into commercial success by bringing together management, funding, and markets. BHI is seeking an experienced life science professional with venture investment experience to join the BHI EIR team and serve as a part time Entrepreneur-in- Residence (EIR) at the National Institutes of Health (NIH) for the National Institute on Aging (NIA).

This position will report to and work closely with our lead at the NIH Office of the Director, Office of Extramural Research and specifically support the portfolio of companies funded by NIA’s ~$130M annual investment in small businesses focused on Alzheimer’s disease & related dementias, disorders of aging and supportive technologies for senior living and care providers.

Click here for more information.

Julie and Rich Bendis

Julie Lenzer, Chief Innovation Officer, The University of Maryland, joins Rich Bendis on BioTalk to discuss Ventures, Collaborations and growing the Quantum footprint in the BioHealth Capital Region.

Listen now via Apple https://apple.co/3on1a9C, Google https://bit.ly/3ovfj4M, Spotify https://spoti.fi/2Qn44hY, and TuneIn https://bit.ly/3w3Au0i.

Julie Lenzer is the Chief Innovation Officer at the University of Maryland and Acting Director for the newly-launched Quantum Startup Foundry. In these roles, she is charged with fostering and deploying innovation to drive economic and social impact from both university-affiliated and community based innovators. She currently oversees UM Ventures, the university’s tech transfer office, the Maryland Small Business Development Center (SBDC), the Maryland International Incubator (MI2), the Mixed/Augmented/Virtual Reality Innovation Center (MAVRIC), as well as university engagement with the Discovery District (UMD’s 150 acre research park). An active angel investor, she is also on the investment committee of the $10M Maryland Momentum Fund.

Cartesian Logo

Gaithersburg, MD, May 4, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced a $2 million competitive R&D award from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to support its clinical development for Descartes-30, the first RNA cell therapy for respiratory diseases.

This is the fourth Small Business Innovation Research (SBIR) grant awarded to Cartesian to support its clinical-stage investigational therapies developed with the company’s proprietary RNA Armory® combination therapy platform.  Cartesian previously won research grants from the National Cancer Institute (NCI) for Descartes-11 in multiple myeloma ($2.3 million) and from the National Institute of Allergy and Infectious Diseases (NIAID) for Descartes-08 in generalized myasthenia gravis ($2 million).

 

ITIF Logo

The rapid development of new COVID-19 vaccines and treatments over the past year is a triumph of innovation. Billions of vaccine doses are being manufactured and should be distributed to all adults globally over the next 18 months. But some argue that suspending intellectual property (IP) rights to allow any company to manufacture vaccines will mean faster access for developing countries. These arguments have culminated in a proposal at the World Trade Organization for a temporary global waiver on COVID-19-related IP rights.